Home » Shionogi’s ADHD Treatment Kapvay Gains FDA Approval
Shionogi’s ADHD Treatment Kapvay Gains FDA Approval
Japanese drugmaker Shionogi has received approval from the FDA for its attention-deficit drug Kapvay. The drug, an oral, nonstimulant, twice-daily therapy, is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents age 6 to 17, Shionogi said. Kapvay (clonidine HCl extended-release) is the first FDA-approved ADHD treatment indicated for use as an add-on therapy to stimulant medication, the company added. The drug also can be taken as a monotherapy.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May